Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,622 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients.
Gatell JM, Morales-Ramirez JO, Hagins DP, Thompson M, Keikawus A, Hoffmann C, Rugina S, Osiyemi O, Escoriu S, Dretler R, Harvey C, Xu X, Teppler H. Gatell JM, et al. Among authors: hoffmann c. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19532. doi: 10.7448/IAS.17.4.19532. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25394041 Free PMC article.
Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial.
Gatell JM, Morales-Ramirez JO, Hagins DP, Thompson M, Arastéh K, Hoffmann C, Raffi F, Osiyemi O, Dretler R, Harvey C, Xu X, Plettenberg A, Smith DE, Portilla J, Rugina S, Kumar S, Frobose C, Wan H, Rodgers A, Hwang C, Teppler H. Gatell JM, et al. Among authors: hoffmann c. Antivir Ther. 2019;24(6):425-435. doi: 10.3851/IMP3323. Antivir Ther. 2019. PMID: 31355775 Clinical Trial.
Everything fine so far? Physical and mental health in HIV-infected patients with virological success and long-term exposure to antiretroviral therapy.
Erdbeer G, Sabranski M, Sonntag I, Stoehr A, Horst HA, Plettenberg A, Schewe K, Unger S, Stellbrink HJ, Fenske S, Hoffmann C. Erdbeer G, et al. Among authors: hoffmann c. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19673. doi: 10.7448/IAS.17.4.19673. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397423 Free PMC article.
Intermittent viraemia and immune reconstitution in patients with more than 10-15 years of antiretroviral therapy: baseline values still matter.
Erdbeer G, Sabranski M, Sonntag I, Stoehr A, Horst HA, Plettenberg A, Schewe K, Unger S, Stellbrink HJ, Fenske S, Hoffmann C. Erdbeer G, et al. Among authors: hoffmann c. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19689. doi: 10.7448/IAS.17.4.19689. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397439 Free PMC article.
Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study).
Schäfer G, Hoffmann C, Arasteh K, Schürmann D, Stephan C, Jensen B, Stoll M, Bogner JR, Faetkenheuer G, Rockstroh J, Klinker H, Härter G, Stöhr A, Degen O, Freiwald E, Hüfner A, Jordan S, Schulze Zur Wiesch J, Addo M, Lohse AW, van Lunzen J, Schmiedel S; IDEAL study group. Schäfer G, et al. Among authors: hoffmann c. AIDS Res Ther. 2019 Nov 15;16(1):34. doi: 10.1186/s12981-019-0250-2. AIDS Res Ther. 2019. PMID: 31729999 Free PMC article. Clinical Trial.
Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial).
Stellbrink HJ, van Lunzen J, Westby M, O'Sullivan E, Schneider C, Adam A, Weitner L, Kuhlmann B, Hoffmann C, Fenske S, Aries PS, Degen O, Eggers C, Petersen H, Haag F, Horst HA, Dalhoff K, Möcklinghoff C, Cammack N, Tenner-Racz K, Racz P. Stellbrink HJ, et al. Among authors: hoffmann c. AIDS. 2002 Jul 26;16(11):1479-87. doi: 10.1097/00002030-200207260-00004. AIDS. 2002. PMID: 12131185 Clinical Trial.
1,622 results